{
  "docId": "019de077-0285-7666-8a7c-e862967898bc",
  "docSlug": "fea13a4d561ba57c72ad56a940de546b",
  "documentTitle": "Evotec | Investor Presentation Deck | 49 slides",
  "authorId": "evotec",
  "authorName": "Evotec",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2024-03-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 39,
  "pageCount": 49,
  "prevPage": 38,
  "nextPage": 40,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de077-0285-7666-8a7c-e862967898bc/39",
  "deckHref": "/decks/019de077-0285-7666-8a7c-e862967898bc",
  "deckJsonHref": "/decks/019de077-0285-7666-8a7c-e862967898bc.json",
  "deckAnchorHref": "/decks/019de077-0285-7666-8a7c-e862967898bc#slide-39",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.628,
        "x": 0.186,
        "y": 0.215
      },
      "kind": "list",
      "text": "Phase II data with BMS in CNS (EVT8683)\nPhase II initiation with Bayer in Kidney Disease\nPhase I data with Kazia in Oncology (EVT801)\nPhase I initiations with Kidney Diseases with other partners\nPhase I initiation with BMS in CNS\nPhase I initiation with BMS in Oncology\nPhase I initiation with Sernova in Diabetes\nPhase I data in Chikungunya virus (EVT894)\nProgress of multiple co-owned equity companies (not disclosed) (e.g., Topas, ...)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2cffa8ce-2a24-4b1f-8f25-de66eb142d19",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.035,
        "w": 0.405,
        "x": 0.186,
        "y": 0.048
      },
      "kind": "title",
      "text": "“Evotec inside” – further progressing",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2f1fb5d3-00e9-420e-ac81-674205466792",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.365,
        "x": 0.186,
        "y": 0.095
      },
      "kind": "title",
      "text": "Selected pipeline events within next 12-24 months",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "971b71b7-82a6-46b3-ae77-cbe9efad067d",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "891ff366-dea4-4f52-bbe9-cfc1beaab0dd",
      "evidence": "list/bullet: Phase II data with BMS in CNS (EVT8683), Phase II initiation with Bayer in Kidney Disease, Phase I data with Kazia in Oncology (EVT801)",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 49,
      "from": 17,
      "beatId": "f8e500c2-a0e1-44fd-9184-3e9083983bf3",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "Call to action for investors and next steps",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}